# Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet

> **NCT03583905** · PHASE3 · COMPLETED · sponsor: **Chong Kun Dang Pharmaceutical** · enrollment: 154 (actual)

## Conditions studied

- Hypertensive Patients With Dyslipidemia

## Interventions

- **DRUG:** CKD-330
- **DRUG:** Placebo of CKD-330
- **DRUG:** D086
- **DRUG:** Placebo of D086
- **DRUG:** D723
- **DRUG:** Placebo of D723

## Key facts

- **NCT ID:** NCT03583905
- **Lead sponsor:** Chong Kun Dang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-04
- **Primary completion:** 2019-07-17
- **Final completion:** 2019-07-17
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03583905

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03583905, "Clinical Trial to Evaluate the Efficacy and Safety of CKD-333 Tablet". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03583905. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*